133 related articles for article (PubMed ID: 1969293)
1. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
Shebuski RJ; Sitko GR; Claremon DA; Baldwin JJ; Remy DC; Stern AM
Blood; 1990 Apr; 75(7):1455-9. PubMed ID: 1969293
[TBL] [Abstract][Full Text] [Related]
2. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
[TBL] [Abstract][Full Text] [Related]
3. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
Mehta JL; Nichols WW; Saldeen TG; Chandna VK; Nicolini FA; Lawson DL; ter Riet MF
J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
[TBL] [Abstract][Full Text] [Related]
4. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
[TBL] [Abstract][Full Text] [Related]
5. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
[TBL] [Abstract][Full Text] [Related]
6. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
7. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
8. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
9. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Khan S; Mehta JL
Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
[TBL] [Abstract][Full Text] [Related]
11. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
[TBL] [Abstract][Full Text] [Related]
12. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
[TBL] [Abstract][Full Text] [Related]
13. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
[TBL] [Abstract][Full Text] [Related]
16. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
[TBL] [Abstract][Full Text] [Related]
17. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
18. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
19. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
[TBL] [Abstract][Full Text] [Related]
20. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
